Back to Search Start Over

In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.

Authors :
Li H
Estabrook M
Jacoby GA
Nichols WW
Testa RT
Bush K
Source :
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2015 Mar; Vol. 59 (3), pp. 1789-93. Date of Electronic Publication: 2014 Dec 22.
Publication Year :
2015

Abstract

Avibactam, a broad-spectrum β-lactamase inhibitor, was tested with ceftazidime, ceftaroline, or aztreonam against 57 well-characterized Gram-negative strains producing β-lactamases from all molecular classes. Most strains were nonsusceptible to the β-lactams alone. Against AmpC-, extended-spectrum β-lactamase (ESBL)-, and KPC-producing Enterobacteriaceae or Pseudomonas aeruginosa, avibactam lowered ceftazidime, ceftaroline, or aztreonam MICs up to 2,048-fold, to ≤4 μg/ml. Aztreonam-avibactam MICs against a VIM-1 metallo-β-lactamase-producing Enterobacter cloacae and a VIM-1/KPC-3-producing Escherichia coli isolate were 0.12 and 8 μg/ml, respectively.<br /> (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)

Details

Language :
English
ISSN :
1098-6596
Volume :
59
Issue :
3
Database :
MEDLINE
Journal :
Antimicrobial agents and chemotherapy
Publication Type :
Academic Journal
Accession number :
25534728
Full Text :
https://doi.org/10.1128/AAC.04191-14